Concepedia

Laurie P. Volak

LP

Statistics

Publications

13

Citations

3.8K

H-Index

13

Active since

2002

Affiliations

Amgen (United States)(Current)

Tufts University

Indiana University – Purdue University Indianapolis

Laurie P. Volak is an author at Amgen (United States) specializing in pharmacology, enzyme inhibition, and medicinal chemistry.

ORCID

Publications per year

2002–2023

13

Publications

13

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Jude Canon, Karen Rex, Anne Y. Saiki et al. · Nature · 2019 · 2.3K citations

, , +14

Discovery of a Covalent Inhibitor of KRAS<sup>G12C</sup> (AMG 510) for the Treatment of Solid Tumors

Brian A. Lanman, Jennifer R. Allen, John G. Allen et al. · Journal of Medicinal Chemistry · 2019 · 722 citations · Full text

, , +16

Curcuminoids Inhibit Multiple Human Cytochromes P450, UDP-Glucuronosyltransferase, and Sulfotransferase Enzymes, whereas Piperine Is a Relatively Selective CYP3A4 Inhibitor

Laurie P. Volak, Senait Ghirmai, John R. Cashman et al. · Drug Metabolism and Disposition · 2008 · 197 citations · Full text

, , +17

Systematic Study of the Glutathione (GSH) Reactivity of<i>N</i>-Arylacrylamides: 1. Effects of Aryl Substitution

Victor J. Cee, Laurie P. Volak, Yuping Chen et al. · Journal of Medicinal Chemistry · 2015 · 154 citations

, , +14

Discovery of <i>N</i>-(1-Acryloylazetidin-3-yl)-2-(1<i>H</i>-indol-1-yl)acetamides as Covalent Inhibitors of KRAS<sup>G12C</sup>

Youngsook Shin, Joon Won Jeong, Ryan P. Wurz et al. · ACS Medicinal Chemistry Letters · 2019 · 105 citations · Full text

, , +15

1–5 of 13